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Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. Early diagnosis offers an approach to achieving
better outcomes. We conducted a blinded-evaluation of prospectively collected preclinical serum from participants in the mul-
timodal group of the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Using isobaric tags (iTRAQ) we identified
90 proteins differentially expressed between OC cases and controls. A second targeted mass spectrometry analysis of twenty
of these candidates identified Protein Z as a potential early detection biomarker for OC. This was further validated by ELISA
analysis in 482 serial serum samples, from 80 individuals, 49 OC cases and 31 controls, spanning up to 7 years prior to diag-
nosis. Protein Z was significantly down-regulated up to 2 years pre-diagnosis (p50.000000411) in 8 of 19 Type I patients
whilst in 5 Type II individuals, it was significantly up-regulated up to 4 years before diagnosis (p50.01). ROC curve analysis
for CA-125 and CA-125 combined with Protein Z showed a statistically significant (p5 0.00033) increase in the AUC from 77
to 81% for Type I and a statistically significant (p5 0.00003) increase in the AUC from 76 to 82% for Type II. Protein Z is a
novel independent early detection biomarker for Type I and Type II ovarian cancer; which can discriminate between both
types. Protein Z also adds to CA-125 and potentially the Risk of Ovarian Cancer algorithm in the detection of both subtypes.
Ovarian cancers (OC) can be classiﬁed into Type I (more indo-
lent tumors lacking mutations in TP53) and Type II (aggres-
sive cancers displaying TP53 mutations in >80% of cases).1
Mortality attributed to OC exceeds that of any gynaeco-
logical cancer,2,3 with 4,272 deaths in the UK in 2011,4 and
an estimated 15,500 deaths in the USA in 2012.5 5 year
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survival rates are >90% in patients with early stage disease
compared with 5% in those with Stage IV disease.6 Identiﬁca-
tion and development of biomarkers capable of detecting OC
early could improve outcomes.
Serum CA-125 is the most widely used biomarker for
OC.7 More recently HE4 has been identiﬁed as an OC
marker that complements CA-125.8 These markers have limi-
tations of speciﬁcity for OC, elevation of serum CA-125 can
also occur in pregnancy, endometriosis and menstruation.7
HE4 is not elevated in these conditions but is elevated in
other cancers.9 Previous efforts to supplement CA-125 with a
broader panel of biomarkers within the Prostate, Lung, Colo-
rectal and Ovarian Cancer Study,10,11 in samples collected at
diagnosis, found putative panels were not discriminatory >6
months prior to diagnosis, perhaps because the biomarkers
were associated with mature tumors.10,11
The most promising strategy for early detection of OC is
a combination of screening using CA-125 (interpreted using
ROCA) with transvaginal ultrasound scanning. In the United
Kingdom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS), this strategy demonstrated a high sensitivity
and speciﬁcity of 89 and 99.8%, respectively,12 on the preva-
lence screen and 85.8% and 99.8%, respectively, at incidence
screening.13 Research is on-going to ascertain the effect of
this screening on mortality and also on its cost effectiveness
for population screening.
A major hurdle in identifying early detection cancer bio-
markers is access to appropriate sample sets for discovery. In
this study, we use prospectively collected specimens in a
blinded evaluation design. Samples were collected from the
UKCTOCS cohort of 202,638 participants representing the
target population envisioned for application of the
biomarker.14
The aim of this study was to identify potential early Stage
OC biomarkers and to ascertain the capacity of these bio-
markers to detect preclinical OC.
Methods
Study subjects and samples
UKCTOCS is a 13 center OC screening trial of 202,638
women and is described in more detail in Supplementary
Methods (available online).
Forty nine women from the multimodal group of UKC-
TOCS diagnosed with invasive epithelial (9 Type I and 30
Type II) and borderline (10) OCs for whom serum samples
were available <14 months and >32 months prior to diagnosis
were identiﬁed. We grouped borderline tumors with Type I for
analysis within this study.15,16 The Type II cases were matched
to 31 controls, with no family history of OC and no diagnosis
of a cancer during follow-up, on age, collection center and col-
lection date. Multiple serial samples were available in these
women—in total; the set consisted of 482 individual samples.
The set was divided into: (i) a discovery set which included all
women but only two samples from each woman, one at <14
months and the other at >32 months prior to diagnosis; and
(ii) a validation set which included all serial samples from the
same women spanning a 7 year period. Supporting Informa-
tion Table 1 contains detailed information on all of these indi-
vidual samples including which were used for iTRAQ,
SWATH, ELISA and detected early by PROZ. It also contains
information on the histology, morphology, grade, stage, age at
which sample was taken and BMI
Isobaric tagging for relative and absolute quantitation
(iTRAQ) analysis
Serum samples from the discovery set above were pooled
according to the two time points into six groups, four contain-
ing cancer samples with 25 individual samples in each and two
control group samples (Supporting Information Table 2). Pool-
ing increases the efﬁcacy of the analysis and averages out indi-
vidual variation.17 Serum was immunodepleted as described in
Supporting Information Methods (available online).
Sequential window acquisition of all theoretical fragment
ion spectra (SWATH) analysis
At the end of 2013 all of the discovery samples underwent
central review, this resulted in 6 Type I samples being reclas-
siﬁed- 3 as Type II and 3 as potential Type II; 2 controls
subject had gone on to get other cancers and one Type II
sample was queried.
From the discovery set new pools were prepared, (con-
taining only those samples conﬁdently classiﬁed by central
review: 19 Type I subjects; the remaining 23 controls and 27
Type II subjects (25 Type II1 3 reclassiﬁed as Type II minus
the queried Type II), according to the two time points, into
six groups’ four containing cancer samples and two control
groups (Supporting Information Table 3).
What’s new?
New biomarkers for the early detection of ovarian cancer (OC) are urgently needed. In this blinded, prospective study, the
authors identified Protein Z as a novel early marker for Type I and Type II OC that can also discriminate between the two
types. When Protein Z levels were combined with CA-125, results for early detection were even better. They may also enhance
the Risk of Ovarian Cancer algorithm. These findings should help researchers develop more sensitive and specific screening
panels for early-stage OC.
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iTRAQ labeling and liquid chromatography mass
spectrometry (LC-MS)
Depleted/buffer exchanged serum protein was reduced and
digested by the addition of trypsin (Promega), then labeled
with 8plex iTRAQ reagents according to the manufacturer’s
instructions (AB Sciex). Labeled samples (Supporting Infor-
mation Table 2) were fractionated and analyzed by MS as
described previously.18
SWATH mass spectrometry
SWATH analysis was carried out as outlined in Ref. 19 fur-
ther details are described in Supporting Information Methods
(available online).
Spectral library creation
A spectral library is required to obtain quantitative protein
information from SWATH maps. For the 20 proteins of
interest (Supporting Information Table 4) peptides were syn-
thesised (JPT peptide Technologies), mixed with indexed
retention time (iRT) peptides (Biognosys AG) and loaded
onto the LC-MS system for analysis. Fragment ion spectra
were combined with spectral information from an in house
database to give the ﬁnal spectral library.20
Protein identification and quantitation
iTRAQ discovery. Mass spectrometry raw data ﬁles were
converted to MGF format and searched, using MASCOT,
against the Swissprot database (2012_11) with Taxonomy set
to Human. MASCOT search parameters are described in
Supporting Information Methods (available online).
SWATH MS targeted data extraction using skyline
Spectral Libraries and raw .WIFF ﬁles from SWATH MS
experiments were imported into Skyline,21 iRT peptides
allowed retention time recalibration and normalization
between samples.22 Protein abundances were estimated from
2 peptides per protein.
ROCA classification
CA-125 results within UKCTOCS were interpreted using the
ROCA rather than a single cut-off. All women randomised to
the multimodal group of the trial underwent annual CA-125
testing and based on the ROCA classiﬁcation, they were
either returned to annual screening (if their risk was normal)
or triaged to repeat CA-125 testing in 3 months (if interme-
diate risk) or repeat CA-125 and transvaginal ultrasound in 6
weeks (if elevated risk).12,23 Those with persistently elevated
risk were sent for clinical assessment with a view to surgery.
The trial protocol is detailed elsewhere.12,23
ELISA validation of protein Z
482 individual serum samples were run in triplicate using
Protein Z ELISAs (Abcam, Cambridge, UK) according to
manufacturer’s instructions. Table 1 includes details of the
set and Table 2 has information on the characteristics of the
primary OCs. Serum CA-125 level concentrations were avail-
able for all of the above samples as previously described.12
Statistical analysis
iTRAQ Channels 119 and 121 were used to label a pool of
all 150 samples from the initial discover phase which were
used to assess technical variation within the work ﬂow, pro-
teins identiﬁed with 2 peptides with a signiﬁcance threshold
of p< 0.05 and having relative ratios outside the 95% conﬁ-
dence intervals were identiﬁed as having signiﬁcant fold
changes.24
Wilcoxon signed rank test, Loess Linear regression, non-
linear modeling, support vector machine learning for ROC
curve construction and MS Stats analysis were all carried out
using the R environment for statistical analysis. All p values
are two tailed and those <0.05 were considered statistically
signiﬁcant.
Results
Subjects
Baseline characteristics for cases and controls are shown in
Table 1. The mean age was 62.8 in cases and 60.8 in controls.
In the Type I cancers, 10 were borderline and of the remain-
ing 9, ﬁve were low grade endometrioid, one was adenocarci-
noma and three were clear cell (Table 2).
Proteomic analysis of OC samples. To study global protein
expression for the detection of early biomarkers of OC,
pooled samples were iTRAQ labeled (Supporting Information
Fig. 1a) and analyzed at <14, >32 months to diagnosis,
(Supporting Information Table 2). Samples were run in tripli-
cate with ninety proteins displaying signiﬁcant differential
expression between cases and controls (Supporting Informa-
tion Table 4 contains detailed information on all the proteins,
including if they have previously been identiﬁed as potential
ovarian cancer biomarkers).
Spectral libraries were created for twenty of these proteins
(Supporting Information Table 4) which were further veriﬁed
using an orthogonal mass spectrometry technique, SWATH
MS (Supporting Information Fig. 1b). New pools were gener-
ated for the Type I and Type II patients along with matched
controls at <14/>32 months prior to diagnosis (Supporting
Information Table 3). SWATH maps were created for each,
in triplicate, interrogated using targeted data extraction via
the spectral libraries above19 and quantitative information
was extracted using Skyline21 and MS Stats.25 Volcano plots
were then constructed (Fig. 1) to identify putative biomarkers
that were most discriminatory between OC cases and control
subjects enabling the identiﬁcation of markers that may be of
utility in early detection.
Validation of early detection biomarkers
Three proteins discriminated between OC cases and control
subjects at all time points identifying them as potential early
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screening biomarkers. These were PGBM; basement
membrane-speciﬁc heparin sulfate proteoglycan core protein,
ADIPO; Adiponectin and PROZ; Vitamin K dependant pro-
tein Z (Protein Z). PGBM is a large (>400 kDa) multido-
main protein which is abundantly expressed in basement
membranes and the ECM of normal blood vessels and tissues
where it maintains the function of the endothelial barrier.26
Adiponectin is an adipocyte-derived cytokine involved in a
number of metabolic processes, including glucose regulation
and fatty acid oxidation. It has anti-inﬂammatory and anti-
atherogenic effects and plays a protective role in experimental
models of vascular injury.27 Protein Z is an anticoagulant
that accelerates the inhibitory effect of PZ-dependent prote-
ase inhibitor on coagulation factor Xa.28
Protein Z was the only one of these three not to have
been associated with OC previously, as a potential novel bio-
marker it was selected for further validation by commercially
available assays. PROZ ELISAs were run in triplicate, on 482
individual serum samples representing 80 individuals; 30
Type II OC women; 31 controls and 19 Type I women, all
with serial serum samples spanning up to 7 years prior to
diagnosis. Table 1 contains information on all samples inves-
tigated. Results for women with Type I and Type II OC ver-
sus healthy control subjects were analyzed separately and
compared with each individuals CA-125 level and ROCA
classiﬁcation.
Protein Z identified as an early marker for Type I OC
Loess linear regression analysis of CA-125 levels for Type I
women (Fig. 2Ia) were compared with their Protein Z levels
(Fig. 2Ib). It was found that as CA-125 levels rise toward
diagnosis (breakpoint 420 days ( 60 weeks) prediagnosis),
there was a mirrored corresponding decrease in the level of
Protein Z.
The Protein Z Loess line tracks below the median value
for the control population dropping more dramatically below
Table 1. Baseline characteristics of UKCTOCS participants used within this study
Median (25th–75th centiles)
Control
Ovarian cancer
Overall Type I Type II
n531 n549 n519 n530
Age (years) at randomisation 60.8 (58.4–65.8) 62.8 (58.7–67.3) 64.2 (58.9–69.9) 61.1 (58.7–65.5)
Years since last period at randomisation 12.6 (6.6–18.2) 11.4 (5.7–18.2) 15.2 (8.1–22.6) 10.7 (4.0–16.1)
Duration of HRT use in those who
were on HRT at randomisation (yrs)
6.9 (5.8–11.7) 9.7 (4.8–13.0) 13.0 (10.7–13.9) 7.2 (3.3–11.6)
Duration of OCP use (yrs) in those
who had used it
10 (3–12) 6 (3–8) 5 (3–8) 6 (4–8)
Miscarriages (pregnancies<6mths) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–0)
No. of children (pregnancies>6mths) 2 (0–2) 2 (2–2) 2 (1–2) 2 (2–3)
Height (cms) 162.6 (158.8–167.6) 162.6 (157.5–165.1) 162.6 (157.5–166.4) 162.6 (157.5–165.1)
Weight (kg) 65.3 (62.6–74.0) 69.9 (62.6–78.9) 71.2 (66.7–79.2) 65.9 (61.7–75.8)
Number (%)
No. % No. % No. % No. %
Ethnicity:
White 30 96.8% 48 98.0% 18 94.7% 30 100.0%
Black 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Asian 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Other 1 3.2% 1 2.0% 1 5.3% 0 0.0%
Missing 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Hysterectomy 1 3.2% 6 12.2% 2 10.5% 4 13.3%
Ever use of oral contraceptive pill 18 58.1% 21 42.9% 9 47.4% 12 40.0%
Use of HRT at recruitment 8 25.8% 9 18.4% 3 15.8% 6 20.0%
Personal history of cancer1 0 0.0% 2 4.1% 1 5.3% 1 3.3%
Personal history of breast cancer 0 0.0% 1 2.0% 1 5.3% 0 0.0%
Maternal history of ovarian cancer 0 0.0% 1 2.0% 0 0.0% 1 3.3%
Maternal history of breast cancer 4 12.9% 4 8.2% 1 5.3% 3 10.0%
1Includes those with personal history of breast cancer.
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the median value at less than 500 days to diagnosis. Some
individuals’ Protein Z values track below the quartile range
during the whole time course and after 500 days to diagnosis
several individuals were below the lowest values identiﬁed in
the control population (Fig. 2Ib) .
To ascertain if this was a real decrease we assessed two
nonlinear models for Protein Z (Fig. 2Ic): level expression as
the optimum method for deﬁning the data; decay in expres-
sion best describing the data. The latter, best deﬁned the data
with a p values5 0.0031 demonstrating that the decrease in
expression is real. The inﬂection point on the Loess plots for
CA-125 and Protein Z occurs at 420 days (60 weeks) prior
to diagnosis. Protein Z levels were placed into 60 weeks bins,
covering the full 7 year timespan and compared with levels
in the control subjects. There was a signiﬁcant decrease in
the Protein Z levels, within the 60 weeks to diagnosis bin,
compared with control levels (p5 0.000000411).
Protein Z complements CA-125 and ROCA in detection of
Type I OC
We next compared the capability of CA-125 and Protein Z
to discriminate between Type I OC patients and healthy con-
trols (Fig. 2II). Protein Z levels signiﬁcantly decreased in
comparison to controls in eight of the 19 cases (patients 1–8,
Supporting Information Table 5); with 25% of the Type I
data points falling below the Protein Z threshold (Fig. 2II);
identifying both invasive and borderline cases at a median of
385.5 days (1 year) prediagnosis, all with Stage I/II disease.
In patients 1–5 CA-125 levels did not rise sufﬁciently for
them to be identiﬁed using CA-125 alone. The eight women
identiﬁed below the Protein Z threshold were ROCA screen
positive (intermediate/elevated risk). For patients 1–5 Protein
Z identiﬁed them substantially earlier than ROCA (Support-
ing Information Table 6).
ROC curves were constructed for CA-125, Protein Z and
for CA-125 and Protein Z combined (Supporting Informa-
tion Fig. 2). The combined panel showed a signiﬁcant
(p5 0.00033) increase in the AUC from 77% for CA-125
alone and 73% for Protein Z alone to 81%.
Protein Z identified as a marker for Type II OC
Loess linear regression analysis of CA-125 levels for Type II
women (Fig. 2IIIa) were compared with their Protein Z levels
(Fig. 2IIIb). The Protein Z Loess line tracks on the median
line for the controls apart from between 1,500 and 500 days
prediagnosis where there is a noticeable rise above then
return to control median values (Fig. 2IIIb).
To ascertain if the trend seen for the Type I patients was
speciﬁc, we tested the nonlinear models used in the Type I
analysis on the Type II dataset, no signiﬁcant trend was dem-
onstrated (Fig. 2IIIc). As with the Type I dataset Protein Z
levels for the Type II cases were placed into 60 weeks bins
and compared with levels in the control subjects. There was
a less marked but signiﬁcant increase in the Protein Z levels
in the 120–180 weeks prediagnosis bin compared with con-
trols (p5 0.0105183).
Protein Z complements CA-125 and ROCA in detection
of Type II OC
We compared the capability of CA-125 and Protein Z to dis-
criminate between Type II OC patients and healthy controls
(Fig. 2IV). Protein Z levels were seen to signiﬁcantly increase
in ﬁve of the 30 Type II cases (Patients 1–5, Supporting
Information Table 7); with 5% of the Type II data points
rising above the Protein Z threshold (Fig. 2IV); cases were
identiﬁed at a median of 1,083 days (3 years) prediagnosis,
with Stage I/II/III disease.
Four patients’ CA-125 levels did not rise sufﬁciently for
them to be identiﬁed using this screening method alone. All
ﬁve women identiﬁed above the Protein Z threshold were
also ROCA screen positive. For these women Protein Z iden-
tiﬁed them substantially earlier than ROCA (Supporting
Information Table 6). ROC curves were constructed for CA-
125, Protein Z and for CA-125 and Protein Z combined
(Supporting Information Fig. 2). The combined panel showed
a signiﬁcant (p5 0.00003) increase in the AUC from 76% for
CA-125 alone and 54% for Protein Z alone to 82%.
Protein Z levels are mutually exclusive for Type I
and Type II OC
We compared whether Protein Z levels could discriminate
between Type I and Type II cases (Fig. 2V). Protein Z is
mutually exclusive for Type I and II, only one of the Type II
data points breaches the low Protein Z Type I threshold and
none of the Type I data points breach the Type II threshold.
More detailed features from Figure 2V showing individual
Table 2. Characteristics of the primary ovarian cancers
No.
Cancer type Overall
Stage
I
Stage
II
Stage
III
Type I 19 14 1 4
Borderline 10 10 0 0
Serous 6 6 0 0
Mucinous 2 2 0 0
Endometrioid 2 2 0 0
Invasive 9 4 1 4
Low grade endometrioid 5 3 1 1
Clear cell 3 0 0 3
Adenocarcinoma 1 1 0 0
Type II 30 7 8 15
High grade serous 23 5 6 12
High grade endometrioid 3 1 1 1
Carcinosarcoma 1 0 0 1
Adenocarcinoma 3 1 1 1
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patient samples and the samples proximity to diagnosis can
be seen in Supporting Information Figure 3.
Discussion
We carried out a blinded evaluation using prospectively col-
lected samples from UKCTOCS14 which contains serum sam-
ples from >200,000 women in the UK, with serial samples
from >50,000 women, spanning a 10 year period. This
enabled us to evaluate putative biomarkers for detection of
preclinical disease.
We employed two unbiased, complementary proteomic
approaches to proﬁle matched serial case control sets of
serum samples. This identiﬁed Protein Z, as a discriminator
between OC cases and controls with potential as an early
screening marker. Protein Z enhances by >1,000 fold the
inhibition of factor Xa by Protein Z dependant protease
inhibitor.29 Deregulation of the haemostatic system is often
seen in malignancy with localised activation of coagulation at
tumor sites facilitating cancer progression.30 Activation of
factor X is critical in the coagulation pathway and it has
been shown to play an important role in the deregulation of
haemostasis seen in malignancy.31 Changes in expression of
Protein Z in OC may be related to its role within this
process.
Comparison of CA-125 and Protein Z in their ability to
identify Type I OC showed that Protein Z expression identi-
ﬁed eight of the 19 Type I OC cases, both invasive and bor-
derline, all with Stage I/II disease. Five of these women
Figure 1. Volcano plots comparing differential expression of the 20 putative early detection biomarkers versus control levels across the
ovarian cancer sub types and time points under investigation. The horizontal dotted line is the 95% confidence interval. Proteins to the
right of the right hand vertical dotted line are at least twofold increased in expression compared with control. Proteins to the left of the left
hand vertical dotted line are at least twofold decreased in expression compared with control. (a) Expression of proteins for Type I ovarian
cancer at the farthest point from diagnosis (>32 months). (b) Expression of proteins for Type I ovarian cancer at the earlier point from diag-
nosis (<14 months). (c) Expression of proteins for Type II ovarian cancer at the farthest point from diagnosis (>32 months). (d) Expression
of proteins for Type II ovarian cancer at the earlier point from diagnosis (<14 months). T
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showed no signiﬁcant elevation in their CA-125 levels and
would therefore not have been diagnosed by analysis of CA-
125 alone. All eight women were ROCA positive,32 ﬁve were
identiﬁed substantially earlier by Protein Z than by ROCA,
adding weight to Protein Z as an early detection marker that
could add to and complement current prediction models for
Figure 2.
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the early detection of Type I OC. Protein Z down regulation
is speciﬁc for the early detection of Type I OC and not a
marker of general malignant progression in OC, as it is not
signiﬁcantly down regulated within Type II OC cases.
Analysis of CA-125 and Protein Z in their ability to iden-
tify Type II OC showed that signiﬁcant up-regulation of Pro-
tein Z allowed the identiﬁcation of ﬁve Type II women. Four
of these women showed no signiﬁcant elevation in their CA-
125 levels and would therefore not have been diagnosed by
the analysis of CA-125 alone. In addition, of the 15 late stage
cases present we found that Protein Z only showed elevated
levels in two, we are uncertain why this is the case. The ﬁve
individuals identiﬁed by an increase in Protein Z expression
were ROCA positive; all ﬁve women were identiﬁed substan-
tially earlier by Protein Z suggesting that in certain Type II
cases it may add to the risk algorithm.
While Protein Z out performed ROCA with a greater lead
time in ﬁve of the Type I women it identiﬁed and 5 of the
Type II women; ROCA is still superior as an estimation tool
for the risk of a women having OC at the time of sampling
as it identiﬁed all of the OC cases within the study.
Current algorithms both for OC screening (ROCA32) and
differential diagnosis of an adnexal mass in symptomatic
patients (OVA133 or ROMA8,34) give signiﬁcant weighting to
CA-125 levels. We constructed ROC curves for CA-125 and
for CA-125 and Protein Z combined. The combined panel
showed a signiﬁcant (p5 0.00033) increase in the AUC from
77% for CA-125 alone to 81% for Type I and a signiﬁcant
(p5 0.00003) increase in the AUC from 76% for CA-125
alone to 82% for Type II OC demonstrating that Protein Z
adds to CA-125 for the detection of Type I and Type II OC.
Unlike most biomarkers which rise toward diagnosis, Pro-
tein Z levels were signiﬁcantly down regulated in Type I OC
compared with those of controls with a median case identiﬁca-
tion time of 385 days (1 year) prior to diagnosis. An impor-
tant consideration here is lead time as the women enrolled in
UKCTOCS who were detected by screening were diagnosed 1–
2 years on average before a clinical diagnosis would have been
made. These results suggest that Protein Z has the ability to
detect OC Type I cases with considerable lead time.
Interestingly Protein Z rose signiﬁcantly in Type II cases
compared with controls with a median case identiﬁcation of
1,083 days (3 years) prediagnosis, taking into account lead
time due to study inclusion, for those cases identiﬁed that
gives a potential lead time of as much as 4 years.
We have established the power of UKCTOCS and the
strength of advanced mass spectrometry/clinical proteomics in
the identiﬁcation of biomarkers for Type I and Type II OC.
We have shown that Protein Z is an early detection biomarker
for both subtypes, with the ability to clearly discriminate
between the two. Protein Z appears to be a better marker for
Type I as it identiﬁed a greater proportion of cases (eight out
of 19) than Type II (ﬁve out of 30) and captured more of the
available Type I data points (25%) compared with Type II
(5%). The identiﬁcation of Protein Z as a potential early
detection biomarker for Type I and Type II OC is signiﬁcant.
Figure 2. Analysis of Type I and Type II ovarian cancer patients within the validation cohort. (I) Analysis of Type I ovarian cancer patient val-
idation cohort (Ia) Loess linear regression analysis of trends in CA-125 levels in Type I subjects. On the right hand side is a violin plot of
the distribution of the CA-125 levels in control subjects. The gray horizontal bars represent the interquartile range of the controls with the
white horizontal line in between being the median level of CA-125 in the control population. The thick black line represents the trend in
the data identified by the Loess analysis. (Ib) Loess linear regression analysis of Protein Z levels in Type I subjects. On the right hand side
is a violin plot of the distribution of the Protein Z levels in control subjects. Ovarian cancer patient Protein Z levels are represented by
circles and individual patient levels over time are shown by connected circles. The gray horizontal bars represent the interquartile range of
the controls with the white horizontal line in between being the median level of Protein Z in the control population. The thick black line
represents the trend in the data identified by the Loess analysis. (ic) Nonlinear modelling of the data from (Ib). Two models were tested,
flat expression represented by the horizontal dashed line and exponential decay represented by the second dashed line. (II) Comparison of
the discriminatory power of CA-125 versus Protein Z for Type I ovarian cancer cases. The vertical line represents the CA-125 threshold
above which women would be sent to a gynecological oncologist (35U ml21). The horizontal line represents the Protein Z threshold which
was selected by taking the 1st percentile of all control samples, representing an empirical estimate of a 1% FDR. The numbers beside cases
ascertains which individuals each point relates to. (III) Analysis of Type II ovarian cancer patient validation cohort. (IIIa) Loess linear regres-
sion analysis of trends in CA-125 levels in all subjects. On the right hand side is a violin plot of the distribution of the CA-125 levels in
control subjects. The gray horizontal bars represent the interquartile range of the controls with the white horizontal line in between being
the median level of CA-125 in the control population. The thick black line represents the trend in the data identified by the Loess analysis.
(IIIb) Loess linear regression analysis of Protein Z levels in all subjects. On the right hand side is a violin plot of the distribution of the Pro-
tein Z levels in control subjects. Ovarian cancer patient Protein Z levels are represented by circles and individual patient levels over time
are shown by connected circles. The gray horizontal bars represent the interquartile range of the controls with the white horizontal line in
between being the median level of Protein Z in the control population. The thick black line represents the trend in the data identified by
the Loess analysis. (IIIc) Nonlinear modelling of the data from (IIIb). Two models were tested flat expression represented by the horizontal
dashed line and exponential decay represented by the second dashed line. (IV) Comparison of the discriminatory power of CA-125 versus
Protein Z for Type II ovarian cancer cases. The vertical line represents the CA-125 threshold above which women would be sent to a gyneco-
logical oncologist (35 U ml21). The horizontal line represents the Protein Z threshold which was selected by taking the 99th percentile, of
all control samples, representing an empirical estimate of a 1% FDR.The numbers beside cases ascertains which individuals each point
relates to. (V) Comparison of Protein Z versus CA-125 levels for Type I OC and Type II OC. The vertical line represents the CA-125 threshold
above which women would be sent to a gynecological oncologist (35 U ml21). The lower PROZ threshold applied to Type-I OC was selected
by taking the 1st percentile and the upper threshold applied to Type-II OC the 99th percentile, of all control samples. This represents an
empirical estimate of a 1% FDR in each case.
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Further validation needs to be carried out before the clini-
cal utility of Protein Z could be implemented, such studies
should include samples from patients with benign tumors and
other unrelated diseases. Once this is completed, one can envi-
sion potential clinical utility of Protein Z within two areas.
The ﬁrst is in its incorporation into current screening proto-
cols, for example, where Protein Z levels could be measured at
the same time as CA-125 levels and both could be assessed
through the ovarian cancer risk estimation algorithm ROCA.
The second could be the incorporation of Protein Z levels
within current algorithms for differential diagnosis of an
adnexal mass in symptomatic patients; where its addition to
the OVA133 or ROMA8,34 could aid in triage of high risk
symptomatic patients presenting at a clinic. This current
work moves us toward both of these possibilities and, with
the addition of other markers, potentially closer to the pro-
duction of discriminatory panels for the identiﬁcation of early
stage OC.
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